==== Reference: Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. (2017) THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7) e0181748.====

Detailed description page of THPdb

This page displays user query in tabular form.

1549 details
Primary information
ThPP IDTh1118
Therapeutic Peptide/Protein NameSulodexide
SequenceNon-protein view full sequnce in fasta
Functional ClassificationIIIc
Molecular Weight5000-8000
Chemical FormulaN.A.
Isoelectric PointN.A.
HydrophobicityN.A.
Melting Point (℃)N.A.
Half Lifeelimination half-life was 11.7 ± 2.0 h by IV route
DescriptionA mixture of glycosaminoglycans (GAGs), composed of dermatan sulfate (DS) and fast moving heparin (FMH).
Indication/DiseaseFor the treatment of thrombosis. Also investigated for use/treatment in diabetic kidney disease, and neuropathy (diabetic).
PharmacodynamicsThe low molecular weight of both sulodexide fractions allows for extensive oral absorption compared to unfractionated heparin. The pharmacological effects of sulodexide differ substantially from other glycosaminoglycans and are mainly characterized by a prolonged half-life and reduced effect on global coagulation and bleeding parameters. Due to the presence of both glycosaminoglycan fractions, sulodexide potentiates the antiprotease activities of both antithrombin III and heparin cofactor II simultaneously.
Mechanism of ActionThrombin inhibition produced by sulodexide is due to the additive effect of its components, namely, heparin cofactor II (HCII) catalysis by dermatan sulfate and antithrombin-III catalysis by fast moving heparin (FMH).
ToxicityN.A.
MetabolismN.A.
AbsorptionSulodexide is absorbed into the blood stream after oral dosing, the absorption rate being equivalent, either calculated from the fast-moving heparin fraction or from the dermatan fraction. Bioavailability following IM administration is approximately 90%.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesAntithrombins and Fibrinolytic Agents and Hypoglycemic Agents and Anticoagulants and Hypolipidemic Agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetHeparin cofactor 2,Antithrombin-III
Information of corresponding available drug in the market
Brand NameSULODEXIDE
CompanySyntex S.A
Brand DiscriptionSulodexide is a highly purified mixture of glycosaminoglycans composed of low molecular weight heparin (80%) and dermatan sulfate (20%)
Prescribed forAntithrombotic and antithrombin activity is of great pharmacologic interest and makes sulodexide a suitable drug for the prophylaxis and treatment of arterial and venous peripheral diseases
Chemical NameN.A.
FormulationN.A.
Physcial AppearnceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful Linkhttp://www.syntexar.com/usr/archivos/99_Sulodexide%20INN%20English.pdf http://en.wikipedia.org/wiki/Sulodexide
PubMed ID25413777, 25112845, 24936534, 24936533, 24936532, 24936531, 12818259, 9436179
3-D StructureN.A.